SAN DIEGO, June 8, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of Jean L. Chan, M.D., as Vice President, Clinical Development, reporting to David T. Hagerty, M.D., Executive Vice President, Clinical Development.
"We are pleased to welcome Jean to the Conatus Clinical Development team," said Dr. Hagerty. "Her substantial academic accomplishments and registration and approval experience are well-suited to our expanding clinical needs, especially as we advance with our initial registration plans. Her demonstrated ability to successfully lead a drug through the approval process and understanding of the metabolic complications of non-alcoholic fatty liver disease bring important capabilities to Conatus. We look forward to her contributions toward advancing emricasan toward regulatory approval and commercial success."
Dr. Chan has been Director, Global Clinical Research - CV/Metabolics, at Bristol-Myers Squibb since 2013, and was Medical Director, Medical Research & Development, at Amylin Pharmaceuticals from 2008 until its acquisition by Bristol-Myers Squibb in 2012. Dr. Chan was the lead clinician for the clinical development of metreleptin (MYALEPT™), including the analysis of the registrational studies, BLA filing strategy, and presentation at the FDA Advisory Committee meeting. She previously served in a series of academic appointments at Harvard Medical School, beginning as a Clinical Fellow in Medicine in 1997 and ending as an Assistant Professor of Medicine in 2008. She held concurrent hospital appointments at Beth Israel Deaconess Medical Center as a Research Associate from 2003 to 2004 and as a Staff Physician from 2004 to 2008, while serving as Attending Physician for the Endocrinology, Diabetes, and Metabolism Clinic and for the Inpatient Endocrinology, Diabetes, and Metabolism Service. Dr. Chan received a M.M.S. in Clinical Investigation from Harvard Medical School, an M.D. from Johns Hopkins University School of Medicine, an M.S. in Computer Science from Johns Hopkins University, and a B.S. in Computer Science from Johns Hopkins University. She is Board Certified in internal medicine, and endocrinology, diabetes and metabolism.
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding advancing emricasan toward regulatory approval and commercial success and emricasan's potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company's prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.